News coverage about OncoGenex Pharmaceuticals (NASDAQ:ACHV) has been trending positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news impact score of 0.27 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7527556093898 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine raised shares of OncoGenex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) remained flat at $$1.34 during trading on Wednesday. The stock had a trading volume of 80,278 shares, compared to its average volume of 86,322. OncoGenex Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $10.23.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) EPS for the quarter.
OncoGenex Pharmaceuticals Company Profile
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.